期刊
CURRENT HYPERTENSION REVIEWS
卷 9, 期 1, 页码 44-59出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1573402111309010008
关键词
Autosomal dominant polycystic kidney disease; AMP-activated protein kinase (AMPK) activators; cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors; mammalian target of rapamycin (mTOR) inhibitors; somatostatin analogues; Src inhibitors; peroxisome proliferator activated receptors (PPAR gamma) agonists; vasopressin V2 receptor antagonists
资金
- NIDDK NIH HHS [P30 DK090728] Funding Source: Medline
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090728] Funding Source: NIH RePORTER
The improvement of imaging techniques over the years has contributed to the understanding of the natural history of autosomal dominant polycystic kidney disease, and facilitated the observation of its structural progression. Advances in molecular biology and genetics have made possible a greater understanding of the genetics, molecular, and cellular pathophysiologic mechanisms responsible for its development and have laid the foundation for the development of potential new therapies. Therapies targeting genetic mechanisms in ADPKD have inherent limitations. As a result, most experimental therapies at the present time are aimed at delaying the growth of the cysts and associated interstitial inflammation and fibrosis by targeting tubular epithelial cell proliferation and fluid secretion by the cystic epithelium. Several interventions affecting many of the signaling pathways disrupted in ADPKD have been effective in animal models and some are currently being tested in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据